Role of Leukotriene Receptor Antagonists in the Management of Pediatric Asthma
Authors:
- 1 October 2012
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 14 (5) , 317-330
Abstract
At present, the main indications for leukotriene receptor antagonists (LTRA) in pediatric asthma are as add-on therapy to inhaled corticosteroids (ICS) and as initial controller therapy in children with mild asthma, especially those who cannot or will not use ICS. LTRA are also useful for patients who have concomitant rhinitis, and patients with viral-induced wheeze and exercise-induced asthma. It should be noted that the benefits of LTRA therapy have been demonstrated in children as young as 6 months of age and recent clinical trials have further proven the benefits of LTRA in acute asthma exacerbations. However, considering the important pro-inflammatory effects that leukotrienes (LT) have in experimental models of asthma, it may seem surprising that LTRA treatment outcomes are not better and that in some clinical trials only a minority of patients could be classified as full responders. This could be explained by potential additional LT receptors that are not affected by LTRA. Such receptors could represent new therapeutic targets in asthma. Furthermore, progress in differentiating between asthma phenotypes that result from different pathogenic mechanisms, some of which may involve LT to a lesser degree, should lead to an improved, personalized use of LTRA for treating asthma.Keywords
This publication has 105 references indexed in Scilit:
- Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller TrialJournal of Allergy and Clinical Immunology, 2011
- Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthmaJournal of Allergy and Clinical Immunology, 2010
- Step-up Therapy for Children with Uncontrolled Asthma Receiving Inhaled CorticosteroidsNew England Journal of Medicine, 2010
- Lessons learned from variation in response to therapy in clinical trialsJournal of Allergy and Clinical Immunology, 2010
- Concentration-Dependent Noncysteinyl Leukotriene Type 1 Receptor-Mediated Inhibitory Activity of Leukotriene Receptor AntagonistsThe Journal of Immunology, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezingJournal of Allergy and Clinical Immunology, 2008
- Azithromycin or montelukast as inhaled corticosteroid–sparing agents in moderate-to-severe childhood asthma studyJournal of Allergy and Clinical Immunology, 2008
- Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?European Journal of Pediatrics, 2008
- Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced BronchoconstrictionNew England Journal of Medicine, 1998